Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MPL | P40238 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 8/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4503529 | 0.90 | ESR1 (0.41) | PTGESLMNAMPLNPC1RAB9A | |
| SCHEMBL4505853 | 0.89 | PTGES (0.46) | PTGESLMNAMPLNPC1RAB9A | |
| SCHEMBL4510070 | 0.87 | PTGES (0.39) | PTGESLMNAMPLNPC1RAB9A | |
| SCHEMBL4497864 | 0.86 | ESR1 (0.42) | PTGESLMNAMPLNPC1RAB9A | |
| SCHEMBL4517757 | 0.86 | ESR1 (0.47) | PTGESLMNACA2CA1CA12 | |
| SCHEMBL4494785 | 0.86 | ESR1 (0.49) | PTGESLMNAMPLNPC1RAB9A | |
| SCHEMBL4510732 | 0.85 | PTGES2 (0.41) | PTGESLMNAMPLCA2CA1 | |
| SCHEMBL4508410 | 0.84 | PTGES (0.41) | PTGESLMNAMPLNPC1RAB9A | |
| SCHEMBL4497549 | 0.83 | PTGES (0.35) | PTGESLMNAMPLCA2CA1 | |
| SCHEMBL4506540 | 0.83 | PTGES (0.40) | PTGESMPLNPC1RAB9ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234014-A1 | Naphthalene-Disulfonamides Useful for the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234014-A1 | Naphthalene-Disulfonamides Useful for the Treatment of Inflammation | AREG, PRSS12, CXCL8 | PTGES 41/4885LMNA 1939/4885MPL 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.